New Delhi, August 12, 2025 — A Delhi court has rejected the anticipatory bail plea of Vicky Ramancha, accused in a massive international scam involving the drug Ozempic worth approximately USD 18.8 million. The court’s decision highlights the gravity of the charges and the necessity of an unobstructed investigation.
A complaint was filed under Section 175(3) of the Bharatiya Nagarik Suraksha Sanhita, 2023 (BNSS) before the Patiala House Court, alleging that Ramancha, along with his Dubai-based company RNR Premier Medical Equipments Trading LLC and US-based RNR Global Procurement Corp, had entered into agreements for the supply of 125,000 doses of Ozempic.
The matter was subsequently referred to the Delhi Police’s Economic Offences Wing (EOW), which, following a court order dated May 29, 2025, registered an FIR under Sections 406 (criminal breach of trust), 420 (cheating), and 120B (criminal conspiracy) of the Indian Penal Code (IPC).
Ozempic, commonly prescribed for Type 2 diabetes, has been the center of a large-scale fraud involving the smuggling and distribution of counterfeit or unauthorized shipments. Ramancha is alleged to be part of a sophisticated network that illegally diverted and sold substandard Ozempic internationally, defrauding pharmaceutical companies and regulatory authorities.
During the bail hearing, Additional Sessions Judge (ASJ) Saurabh Laler of the Patiala House Court observed that the scale of the alleged fraud and the serious health risks posed by exporting spurious pharmaceuticals to the United States made it inappropriate to grant anticipatory bail.
The court further noted that granting bail at this stage could jeopardize the investigation by enabling tampering with evidence or influencing witnesses.
With the anticipatory bail plea rejected, Ramancha remains vulnerable to arrest as the investigation continues, involving coordination with international agencies to dismantle the wider fraud network.
This case underscores the judiciary’s firm stance against cross-border pharmaceutical fraud and its commitment to safeguarding public health and legal accountability.